OCUP Stock Price, Ocuphire Pharma, Inc. Quote, Chart

Market Summary

USD1.68-0.06

Delayed

-3.45%

OCUP Stock Price

View Fullscreen

OCUP RSI Chart

OCUP Valuation

Market Cap

43.6M

Price/Earnings (Trailing)

-3.85

Price/Sales (Trailing)

2.29

EV/EBITDA

0.32

Price/Free Cashflow

-13.69

OCUP Price/Sales (Trailing)

OCUP Profitability

EBT Margin

-59.38%

Return on Equity

-24.54%

Return on Assets

-21.8%

Free Cashflow Yield

-7.31%

OCUP Fundamentals

OCUP Revenue

Revenue (TTM)

19.0M

Rev. Growth (Yr)

798.04%

Rev. Growth (Qtr)

224.85%

OCUP Earnings

Earnings (TTM)

-11.3M

Earnings Growth (Yr)

-22.71%

Earnings Growth (Qtr)

-48.2%

Breaking Down OCUP Revenue

Last 7 days

-2.3%

Last 30 days

-3.4%

Last 90 days

-36.1%

Trailing 12 Months

-61.4%

How does OCUP drawdown profile look like?

OCUP Financial Health

Current Ratio

8.96

OCUP Investor Care

Shares Dilution (1Y)

23.73%

Diluted EPS (TTM)

-0.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	19.0M	0	0	0
2023	34.6M	29.4M	24.2M	19.0M
2022	0	0	0	39.9M
2021	0	1.3M	589.0K	20.2M
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	0
2014	0	0	0	0
2013	0	0	0	0
2012	0	0	0	0
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ocuphire Pharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	pepose jay	acquired	-	-	32,000	-
Mar 21, 2024	schachle joseph k	bought	4,100	2.05	2,000	chief operating officer
Mar 21, 2024	jhaveri nirav s.	bought	21,000	2.1	10,000	chief financial officer
Mar 18, 2024	magrath george	bought	49,050	1.962	25,000	chief executive officer
Feb 12, 2024	jhaveri nirav s.	acquired	-	-	140,000	chief financial officer
Feb 12, 2024	jayagopal ashwath	acquired	-	-	75,000	chief scientific & dev. ofc.
Jan 18, 2024	zaremba rabourn amy	acquired	-	-	40,000	svp of finance
Jan 18, 2024	hoffmann bernhard	acquired	-	-	20,000	svp of corp. dev.
Jan 10, 2024	patel ronil a.	sold (taxes)	-4,185	3.265	-1,282	chief business officer
Jan 10, 2024	zaremba rabourn amy	sold (taxes)	-12,896	3.265	-3,950	svp of finance

Which funds bought or sold OCUP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	-30,000	60,300	-%
May 16, 2024	FSA Wealth Management LLC	unchanged	-	10.00	10.00	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-104,420	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-99.97	-47,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	added	420	113,877	159,855	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-70,473	141,651	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-56,114	112,789	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-81.00	-	-%
May 15, 2024	Diametric Capital, LP	reduced	-29.92	-117,425	103,301	0.06%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	14,826	14,826	-%

Are Funds Buying or Selling OCUP?

Are funds buying OCUP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OCUP

No. of Funds

Unveiling Ocuphire Pharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	sooch mina	5.5%	1,187,352	SC 13G/A
May 17, 2022	richmond brothers, inc.	5.84%	1,123,539	SC 13G
Feb 14, 2022	altium capital management lp	4.99%	384,615	SC 13G/A
Feb 14, 2022	sooch mina	6.7%	1,286,262	SC 13G/A
Jan 18, 2022	empery asset management, lp	4.99%	3,063,498	SC 13G/A

Recent SEC filings of Ocuphire Pharma, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	8-K	Current Report
May 10, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 19, 2024	PRE 14A	PRE 14A
Apr 17, 2024	8-K	Current Report
Apr 15, 2024	4	Insider Trading
Mar 27, 2024	8-K	Current Report

Peers (Alternatives to Ocuphire Pharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Ocuphire Pharma, Inc. News

Latest updates

Ocuphire Pharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4	2021Q3	2021Q2	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	1.2%	1,711,000	1,691,000	11,935,000	3,674,000	1,749,000	1,329,000	909,000	489,000	100,000	-	-	1,150,000	-	-	-	-	-	-	-	-	-
Operating Expenses	32.3%	9,419,000	7,120,000	5,549,000	9,063,000	7,880,000	5,640,000	6,150,000	4,721,000	7,237,000	1,948,000	1,262,000	2,735,000	-5,013,793	2,280,624	2,988,417	3,937,752	4,966,470	4,683,907	5,001,441	-	-
S&GA Expenses	-100.0%	-	3,279,000	2,055,000	4,340,000	2,285,000	2,054,000	1,414,000	1,595,000	3,408,000	565,000	551,000	391,000	-2,364,744	1,149,206	1,340,016	1,695,523	2,236,493	1,795,952	1,568,848	1,827,322	-
R&D Expenses	-	-	-	-	-	-	-	-	-	-	149,594	231,607	456,790	454,728	1,131,418	1,648,401	2,242,229	2,729,977	2,887,955	3,432,593	4,058,533	-
EBITDA Margin	-13.4%	-0.59	-0.52	1.20	0.64	0.55	0.46	-2.80	-108	-48.38	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	2,000	-	-	179,000	689,000	554,000	-	-	-	-	-	-	-	-	-
Income Taxes	100.0%	-	-2,000	14,000	-	-	315,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-48.1%	-7,106,000	-4,797,000	5,575,000	-4,961,000	-5,791,000	34,256,000	-6,313,000	-4,230,000	-7,136,000	-1,248,000	-1,604,000	-3,088,000	-	-	-	-	-	-	-	-	-
EBT Margin	-13.4%	-0.59	-0.52	1.20	0.64	0.55	0.46	-2.80	-117	-52.86	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-48.2%	-7,106,000	-4,795,000	5,561,000	-4,961,000	-5,791,000	33,941,000	-6,313,000	-4,230,000	-7,136,000	-1,248,000	-1,604,000	-3,088,000	597,510	-1,959,230	-2,464,284	-2,342,996	-3,116,570	-5,338,819	-3,838,268	-	-
Net Income Margin	-13.4%	-0.59	-0.52	1.19	0.63	0.54	0.45	-2.80	-117	-52.86	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-225.7%	-5,716,000	4,548,000	-3,003,000	989,000	-3,646,000	28,791,000	-5,646,000	-3,584,000	-4,328,000	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.9%	52.00	54.00	54.00	43.00	45.00	49.00	15.00	18.00	20.00	26.00	23.00	25.00	12.00	18.00	9.00	10.00	12.00	2.00	15.00	18.00	19.00
Current Assets	-3.9%	52.00	54.00	54.00	43.00	45.00	49.00	15.00	18.00	20.00	26.00	23.00	25.00	12.00	18.00	9.00	10.00	11.00	2.00	15.00	17.00	19.00
Cash Equivalents	-6.6%	47.00	51.00	42.00	40.00	39.00	43.00	14.00	17.00	19.00	25.00	22.00	24.00	11.00	16.00	1.00	1.00	1.00	2.00	8.00	7.00	6.00
Net PPE	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	43.2%	6.00	4.00	4.00	6.00	4.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	2.00	31.00	3.00	3.00	2.00	9.00	3.00	4.00	3.00
Current Liabilities	43.2%	6.00	4.00	4.00	6.00	4.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	2.00	3.00	3.00	3.00	2.00	9.00	3.00	4.00	3.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	0.00	1.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-7.7%	46.00	50.00	50.00	38.00	41.00	46.00	12.00	15.00	17.00	22.00	21.00	23.00	10.00	-	6.00	7.00	9.00	10.00	12.00	14.00	16.00
Retained Earnings	-8.7%	-88.57	-81.47	-76.67	-82.23	-77.27	-71.48	-105	-100	-95.96	-89.37	-83.05	-78.82	-71.69	-32.67	-167	-166	-163	-8.05	-161	-159	-157
Additional Paid-In Capital	2.5%	135	131	127	120	119	118	117	115	113	112	104	101	82.00	19.00	174	173	173	0.00	173	173	173
Shares Outstanding	4.6%	25.00	24.00	23.00	21.00	21.00	21.00	20.00	19.00	19.00	19.00	14.00	14.00	11.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	89.00	-	-	-	37.00	-	-	-	84.00	-	-	-	11.00	-	-	-	21.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-225.7%	-5,716	4,548	-3,003	989	-3,646	28,791	-4,498	-3,809	-6,170	-5,646	-3,584	-4,328	-5,812	-4,358	-1,056	-651	-732	4,972	-2,377	-1,806	-4,380
Share Based Compensation	38.5%	985	711	573	1,422	804	424	493	445	445	479	478	463	494	513	616	316	61.00	-71.35	91.00	128	161
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-100	-	-	-	539	-	-	-	-123	3,000	2,994	-5,895
Cashflow From Financing	-34.1%	2,376	3,603	5,376	-	-	-12.00	1,328	1,588	882	8,030	1,600	17,965	10.00	19,496	924	252	448	-2,949	-	-	7,654

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OCUP Income Statement

2024-03-31

Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Statements of Comprehensive Loss [Abstract]
License and collaborations revenue	$ 1,711	$ 1,749
Operating expenses:
General and administrative	4,670	2,285
Research and development	4,749	5,595
Total operating expenses	9,419	7,880
Loss from operations	(7,708)	(6,131)
Fair value change in derivative liabilities	0	0
Other income, net	602	340
Loss before income taxes	(7,106)	(5,791)
Benefit (provision) for income taxes	0	0
Net loss	(7,106)	(5,791)
Other comprehensive loss, net of tax	0	0
Comprehensive loss	$ (7,106)	$ (5,791)
Net loss per share:
Basic (in dollars per share)	$ (0.29)	$ (0.28)
Diluted (in dollars per share)	$ (0.29)	$ (0.28)
Number of shares used in per share calculations:
Basic (in shares)	24,520,475	20,939,607
Diluted (in shares)	24,520,475	20,939,607

OCUP Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 47,161	$ 50,501
Accounts receivable	1,924	926
Contract assets and unbilled receivables (Note 9)	1,194	1,407
Prepaids and other assets	1,560	1,099
Short-term investments	5	15
Total current assets	51,844	53,948
Property and equipment, net	0	0
Total assets	51,844	53,948
Current liabilities:
Accounts payable	2,064	2,153
Accrued expenses	3,649	1,815
Derivative liability	74	74
Total current liabilities	5,787	4,042
Total liabilities	5,787	4,042
Commitments and contingencies (Note 3 and Note 8)
Stockholders' equity:
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023.	0	0
Common stock, par value $0.0001; 75,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 25,085,592 and 23,977,491 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.	3	2
Additional paid-in capital	134,626	131,370
Accumulated deficit	(88,572)	(81,466)
Total stockholders' equity	46,057	49,906
Total liabilities and stockholders' equity	$ 51,844	$ 53,948

About Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.

CEO	Mr. Richard J. Rodgers M.B.A.
WEBSITE	ocuphire.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Ocuphire Pharma, Inc. Frequently Asked Questions

What is the ticker symbol for Ocuphire Pharma, Inc.? What does OCUP stand for in stocks?

OCUP is the stock ticker symbol of Ocuphire Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocuphire Pharma, Inc. (OCUP)?

As of Fri May 17 2024, market cap of Ocuphire Pharma, Inc. is 43.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCUP stock?

You can check OCUP's fair value in chart for subscribers.

What is the fair value of OCUP stock?

You can check OCUP's fair value in chart for subscribers. The fair value of Ocuphire Pharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocuphire Pharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCUP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocuphire Pharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether OCUP is over valued or under valued. Whether Ocuphire Pharma, Inc. is cheap or expensive depends on the assumptions which impact Ocuphire Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUP.

What is Ocuphire Pharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OCUP's PE ratio (Price to Earnings) is -3.85 and Price to Sales (PS) ratio is 2.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ocuphire Pharma, Inc.'s stock?

In the past 10 years, Ocuphire Pharma, Inc. has provided -0.426 (multiply by 100 for percentage) rate of return.